Palliative Care Consultations Underused, Happen Too Late in High-Grade Glioma
About 1 in 10 patients with high-grade glioma had a palliative care consultation before the end-of-life phase, researchers found.
Diagnosis & Disease Information
Bevacizumab Biosimilar Alymsys Now Available
Alymsys (bevacizumab-maly), a biosimilar to Avastin (bevacizumab), has been made available by Amneal Pharmaceuticals.
Bevacizumab Biosimilar Vegzelma Gets FDA Approval
Vegzelma is a vascular endothelial growth factor inhibitor.
Retifanlimab, HFRT, and Bevacizumab Produce “Encouraging” Results in Recurrent Glioblastoma
Combination retifanlimab, hypofractionated radiotherapy, and bevacizumab met the primary endpoint in a phase 2 trial of patients with recurrent glioblastoma.
Depatuxizumab Mafodotin Does Not Improve Overall Survival in Glioblastoma
Depatuxizumab mafodotin does not improve overall survival when added to radiotherapy and temozolomide in newly diagnosed glioblastoma.
Veliparib With Adjuvant Temozolomide May Benefit Select Patients With Glioblastoma With MGMT Promoter Hypermethylation
A subset of patients treated with temozolomide plus veliparib may have extended survival following retreatment with temozolomide at first recurrence.
Temozolomide Bests Nivolumab in Glioblastoma With Unmethylated MGMT Promoter
Overall and progression-free survival were superior with temozolomide.
Cell Phone Use Does Not Increase the Risk of Brain Tumors, Study Suggests
Researchers found no increased risk of any brain tumors among cell phone users.
Adding Nivolumab to Standard Care Does Not Improve Survival in Glioblastoma
The median PFS was 10.6 months in the nivolumab group and 10.3 months in the placebo group.
Adding Marizomib to Standard Care Did Not Improve Survival in Newly Diagnosed Glioblastoma
There was no improvement in progression-free or overall survival with marizomib.
- Loading...
Loading...
Next post in Brain Cancer
Loading... 
Loading...